PTC Therapeutics Inc

PTCT remains in Stage 2 advancing corrective uptrend within a long-term uptrend. The pullback has respected rising 50 SMA and EMAs as support, marking a healthy corrective reset. An active Lockout Rally indicates forced participation driving upside repricing. Short-term pullback entry into these EMAs offers favorable execution. Buy Now to participate in continuation while support holds.

• ↑Q1 2026 revenue $273M (+47% YoY), Suffiance $125M (+36% QoQ)
• ↑2026 product revenue guidance upped to $750–$850M
• ↓Shares trade ~2× GF Value ($36 vs $78), signaling overvaluation